Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (41)

2024

  1. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

  2. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

    Clinical and Translational Oncology

  3. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

    Revista Espanola de Cardiologia

  4. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study

    Annals of the Rheumatic Diseases

  5. Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey

    Journal of Headache and Pain, Vol. 25, Núm. 1

  6. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55

2023

  1. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  2. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

2022

  1. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

    Oral Oncology, Vol. 115

  3. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

    Mycoses, Vol. 64, Núm. 1, pp. 66-77

  4. The patient's perspective on treatment with dacomitinib: Patient-reported outcomes from the Phase III trial ARCHER 1050

    Future Oncology, Vol. 17, Núm. 7, pp. 783-794

  5. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

    The Lancet, Vol. 398, Núm. 10315, pp. 1984-1996

  6. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Drugs, Vol. 81, Núm. 2, pp. 257-266

2019

  1. Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer

    Future Oncology, Vol. 15, Núm. 24, pp. 2795-2805

  2. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: A pooled safety analysis

    Future Oncology, Vol. 15, Núm. 13, pp. 1481-1491

2018

  1. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations

    Journal of Clinical Oncology, Vol. 36, Núm. 22, pp. 2244-2250

  2. Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

    Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174

2017

  1. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in spain

    ClinicoEconomics and Outcomes Research, Vol. 9, pp. 39-47